Species |
Mouse |
Protein Construction |
Flag |
His |
APRIL/TNFSF13 (Ala96-Leu241)_x000D_ Accession # Q9D777 |
N-term |
|
C-term |
|
Purity |
> 90% as determined by BisTris PAGE > 90% as determined by HPLC |
Endotoxin Level |
Less than 1EU per μg by the LAL method. |
Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized APRIL/TNFSF13, His & Flag, Mouse at 0.5μg/ml (100μl/well) on the plate can bind Mouse BCMA, hFc Tag. Test result was comparable to standard batch. |
Expression System |
HEK293 |
Theoretical Molecular Weight |
18.53 kDa |
Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 24-30 kDa based on Bis-Tris PAGE result. |
Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Target Background |
The APRIL (a proliferation-inducing ligand), also known as TNFSF13, TALL2, TRDL1, and CD256, is a member of the TNF ligand superfamily.Both APRIL and its close relative BAFF bind and signal through the TNF superfamily receptors TACI and BCMA, while BAFF additionally functions through BAFF R. |
Synonyms |
CD256; TALL2; TALL-2; TNFSF13; APRIL; APRILFLJ57090; TRDL1; TRDL-1; ZTNF2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.